The inclusion of familial myeloid malignancies as a separate disease entity in the revised WHO classification has renewed efforts to improve the recognition and management of this group of at risk individuals. Here we report a cohort of 86 acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) families with 49 harboring germline variants i...
Barrachina, María NSueiro, Aurelio MIzquierdo, IreneHermida-Nogueira, LidiaGuitián, EstebanCasanueva, Felipe FFarndale, RichardMoroi, MasaakiJung, StephaniePardo, María
...
Abstract: Background and aims: Platelets play a fundamental role in the increased atherothrombotic risk related to central obesity since they show hyperactivation and lower sensitivity to antiplatelet therapy in obese patients. The main goal of this study was to identify platelet biomarkers related to the risk of suffering atherothrombosis in obese...
Citalopram, a selective serotonin reuptake inhibitor (SSRI), inhibits platelet function in vitro. We have previously shown that this action is independent of citalopram’s ability to block serotonin uptake by the serotonin transporter and must therefore be mediated via distinct pharmacological mechanisms. We now report evidence for two novel and put...
Mori, JunNagy, ZoltanDi Nunzio, GiadaSmith, Christopher WGeer, Mitchell JAl Ghaithi, Rashidvan Geffen, Johanna PHeising, SilkeBoothman, LukeTullemans, Bibian ME
...
Src family kinases (SFKs) coordinate the initiating and propagating activation signals in platelets, however it remains unclear how they are regulated. Here we show that ablation of C-terminal Src kinase (Csk) and receptor-like protein tyrosine-phosphatase CD148 in mice results in a dramatic increase in platelet SFK activity, demonstrating that the...
Summary. Background: Platelet collagen receptor GPVI binds collagen, initiating thrombogenesis and stabilizes thrombi by binding fibrin. Objectives: To determine if GPVI-dimer, monomer, or both bind to fibrinogen substrates, and which region common to these substrates contains the interaction site. Methods: Recombinant GPVI monomeric extracellular ...
Following platelet adhesion and primary activation at sites of vascular injury, secondary platelet activation is induced by soluble platelet agonists, such as ADP, ATP, thrombin and thromboxane. Zinc ions are also released from platelets and damaged cells and have been shown to act as a platelet agonist. However, the mechanism of zinc-induced plate...